A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/496 (2006.01) A61P 25/00 (2006.01) A61P 25/14 (2006.01) A61P 25/18 (2006.01) A61P 25/22 (2006.01) A61P 25/24 (2006.01) A61P 25/28 (2006.01) A61P 27/02 (2006.01) A61P 27/06 (2006.01)
Patent
CA 2410618
This invention relates to pharmaceutical compositions containing S-methyl- dihydro-ziprasidone and to the use of such compound and its pharmaceutically acceptable salts for the treatment of psychiatric and ocular disorders. More specifically, it relates to the use of such compound and its pharmaceutically acceptable salts for the treatment of a disorder or condition selected from: schizophrenia, anxiety disorders such as generalized anxiety disorder, panic disorder, posttraumatic stress disorder and phobias (e.g., social phobia, agoraphobia etc.); psychotic episodes of anxiety: anxiety, agitation, excessive aggression, tension, or social or emotional withdrawal associated with psychosis; psychotic mood disorders such as severe major depressive disorder; mood disorders associated with psychotic disorders such as acute mania and depression associated with bipolar disorder, and mood disorders associated with schizophrenia; behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder; dementias such as dementias associated with Alzheimer's disease; drug-induced and neurodegeneration based dyskinesias; obsessive compulsive disorder; Tourette's syndrome; glaucoma; and ischemic retinopathy.
La présente invention concerne des compositions pharmaceutiques contenant S-méthyl-dihydroziprasidone ainsi que l'utilisation de ce composé et de ses sels acceptables sur le plan pharmaceutique dans le traitement des troubles psychiatriques et oculaires. Plus particulièrement, cette invention concerne l'utilisation de ce composé et de ses sels acceptables sur le plan pharmaceutique pour le traitement d'un trouble ou d'un état pathologique tels que: schizophrénie, anxiété, notamment le trouble d'anxiété généralisée, le trouble panique, le trouble de stress post-traumatique et les phobies (par exemple, la phobie sociale, l'agoraphobie, etc.); d'épisodes psychotiques de l'anxiété: anxiété, agitation, agressivité excessive, tension, retrait social ou affectif associé à la psychose; de troubles psychotiques de l'humeur, tel que le trouble dépressif majeur grave; de troubles de l'humeur associés à des troubles psychotiques tels que la manie aiguë et la dépression associées à un trouble bipolaire, et les troubles de l'humeur associés à la schizophrénie; de troubles du comportement associés à une déficience mentale, à un trouble auditif, et à un trouble de la conduite; de démences, notamment celles associées à la maladie d'Alzheimer; de la dyskinésie d'origine médicamenteuse et neurodégénérative; de troubles compulsifs obsessionnels; du syndrome de Tourette; du glaucome; et de la rétinopathie ischémique.
Prakash Chandra Aggarwal
Smolarek Teresa Annette
Pfizer Products Inc.
Smart & Biggar
LandOfFree
S-methyl-dihydro-ziprasidone for treatment of psychiatric... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with S-methyl-dihydro-ziprasidone for treatment of psychiatric..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and S-methyl-dihydro-ziprasidone for treatment of psychiatric... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1479459